Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Spondyloarthritis, encompassing conditions like ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), presents significant challenges in patient care due to chronic inflammation and pain. The development of targeted therapies has transformed management strategies, and Upadacitinib Hemihydrate, a selective JAK1 inhibitor, is playing an increasingly vital role.
Upadacitinib Hemihydrate's efficacy in treating axial spondyloarthritis has been rigorously demonstrated through clinical trials. For patients with active AS, who often experience inadequate response to conventional therapies, Upadacitinib Hemihydrate offers a new oral treatment option. It targets the JAK1 pathway, crucial for mediating inflammatory signals in conditions like AS, leading to significant improvements in disease activity, back pain, and physical function.
Similarly, for nr-axSpA, a condition where inflammation cannot be detected by X-ray but causes significant symptoms, Upadacitinib Hemihydrate has shown promising results. Clinical studies indicate that it provides rapid and meaningful disease control, with patients achieving ASAS40 responses at week 14, a key indicator of therapeutic success. This offers a vital treatment avenue for patients with limited options.
Beyond spondyloarthritis, Upadacitinib Hemihydrate is also recognized for its impact on other inflammatory diseases. Its application in conditions like rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease further highlights its versatility and importance in managing a broad spectrum of immune-mediated disorders. The oral formulation simplifies treatment, enhancing patient compliance.
The safety profile of Upadacitinib Hemihydrate has been extensively evaluated, showing consistency across various indications. While generally well-tolerated, it's essential for patients and healthcare providers to be aware of potential side effects and contraindications. The availability of Upadacitinib Hemihydrate marks a significant step forward in providing effective and targeted treatment for spondyloarthritis and other inflammatory conditions, improving patient outcomes and quality of life.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
